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Abstract  
Germany is the highest populated country in Europe with a population of 82.3 million in 2019. As in many other developed countries, it 
has an aging population. Approximately 10% of the gross domestic product is spent on healthcare. The healthcare system is 
characterized by its accessibility. Patients are generally free to choose their primary care physicians, both family doctors and 
specialists, pharmacy, dentist, or emergency service. Up to a certain income, health insurance is mandatory with the statutory health 
insurance (SHI) system, covering 88% of the population. Major challenges are the lack of cooperation and integration between the 
different sectors and healthcare providers. This is expected to change with the introduction of a telematic infrastructure that is 
currently being implemented. It will not only connect all providers in primary and secondary care in a secure network but will also 
enable access to patients’ electronic record/medical data and at the same time switch from paper to electronic prescriptions. 
Approximately 52,000 of the 67,000 pharmacists are working in approximately 19,000 community pharmacies. These pharmacies are 
owner-operated by a pharmacist. Pharmacists may own up to three subsidiaries nearby to their main pharmacy. Community pharmacy 
practice mainly consists of dispensing drugs, counselling patients on drug therapy and safety, and giving advice on lifestyle and healthy 
living. Many cognitive pharmaceutical services have been developed and evaluated in the past 20 years. Discussions within the 
profession and with stakeholders on the national level on the roles and responsibilities of pharmacists have resulted in nationally 
agreed guidelines, curricula, and services. However, cognitive services remunerated by the SHI funds on the national level remain to be 
negotiated and sustainably implemented. A law passed in November 2020 by parliament will regulate the remuneration of 
pharmaceutical services by the SHI funds with an annual budget of EUR 150 million. The type of services and their remuneration 
remain to be negotiated in 2021. The profession has to continue on all levels to advocate for a change in pharmacy practice by 
introducing pharmacy services into routine care. 
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THE GERMAN HEALTHCARE SYSTEM 
Germany consists of 16 partly sovereign federal states. In 
2018, Germany’s annual gross domestic product amounted 
to approx. EUR 3,356 billion, 11.7% (EUR 391 billion) of 
which was spent on healthcare, with an expenditure rate of 
EUR 4,712 per inhabitant.1 
With 83.2 million inhabitants in 2019, Germany is the 
highest populated country in the European Union. Life 
expectancy has reached 78.5 years for newborn males and 
83.3 years for females. Germany’s population is aging 
rapidly, with the largest group, 23.9 million (2018), being 
40-59-year-olds. The next-largest age group is 65 years and 
older, at 17.9 million.2 The demographic change in 
Germany is expected to increase the future demand for 
healthcare services and related expenditures.3 
Health insurance is mandatory, either through statutory 
health insurance (SHI) or private insurance.4 The 
contribution rate in the SHI is 14.6% of the salary up to an 
income threshold in 2021 of EUR 4,837.50 per month, of 
which employers pay half. Private health insurance is only 
available for employees whose monthly income exceeds a 
certain threshold (EUR 5,362.50 in 2021) or by persons that 
are self-employed.  
The SHI system covers 88% of the population i.e., 
approximately 73.3 million people. In 2019, total 
expenditures of the SHI were about EUR 252 billion (+5.3% 
from 2018), of which most was spent for hospitals (EUR 81 
billion), followed by drugs (EUR 43 billion).5 More than 100 
SHI funds remunerate providers for inpatient and 
outpatient care, and prescription drug coverage for 
pharmacies, in a single national formulary that covers all 
drugs authorized nationally or by the European Medicines 
Agency (EMA), limiting patients’ copayment to a maximum 
of EUR 10 per prescribed drug.4  
 
PRIMARY CARE IN GERMANY 
The German healthcare system consists of a network of 
around 1,900 hospitals, approximately 150,000 ambulatory 
care/office-based physicians, and 19,000 community 
pharmacies. Primary care physicians treating SHI insured 
patients are organized in regional associations and provide 
all ambulatory medical care. The regional associations 
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negotiate the overall budgets prospectively for their 
members with the SHI funds and refund the physicians for 
the provided services on a quarterly basis.6 General 
practitioners make up 49% of office-based physicians.7  
General practitioners and community pharmacies often 
serve as the first contact for patients in cases of health 
complaints. Patients are generally free to choose their 
physician (general practitioners and specialists), pharmacy, 
dentist, or emergency service. The German ambulatory 
sector is characterized by a high number of healthcare 
providers per inhabitant and, hence, good accessibility to 
care.8 However, due to the lack of a formal gatekeeper 
system, especially in primary care, physician hopping is 
observed.9 
 
GERMAN COMMUNITY PHARMACIES 
Community pharmacies are a major component of the 
German healthcare system. In addition to dispensing drugs, 
pharmacists and pharmacy technicians provide counselling 
about dosing, application, potential adverse effects, and 
drug/drug- or drug/food-interactions, complemented by 
advice given on lifestyle and healthy living e.g., nutrition 
counselling and preventive care.10,11 In 2019, over 52,000 of 
the approximately 67,000 pharmacists worked in 
community pharmacies.  
A third-party pharmacy ownership ban means that all 
community pharmacies are owner-operated by a 
pharmacist. Pharmacists may operate up to three 
subsidiaries nearby their main pharmacy, with one 
pharmacist each as a mandatory subsidiary manager. 
Therefore, no pharmacy chains exist in Germany. A license 
is required to operate a pharmacy, as stipulated by the 
German Pharmacy Act. Although the establishment of a 
new pharmacy is not state-regulated e.g., regarding 
pharmacy numbers, density or population, the number of 
community pharmacies has continuously declined since 
2009. In 2019, there were 19,075 community pharmacies, 
of which 4,602 were subsidiaries. On average, there are 23 
pharmacies for every 100,000 residents, which is below the 
mean for the EU (32/100,000 residents).12 
In Germany, there is a strict distinction between drugs only 
available in pharmacies (pharmacy-only drugs, including 
prescription-only and controlled drugs) and freely available 
drugs (e.g., many herbals and diet supplements), also sold 
by drug stores and supermarkets (general sales list). Typical 
non-prescription medicines such as analgesics, NSAIDs, 
paracetamol, cough and cold medicines, among others, are 
pharmacy-only products. Hence, there is a wide range 
monopoly on drugs for pharmacies. In total, pharmacies 
dispensed 1,376 million drug packages in 2019, including 
760 million packages of prescription-only drugs (55.3%). 
Since 2013, the pharmacy sales price for prescription drugs 
is determined by adding a margin of 3% to the wholesale 
price, plus a fixed pharmacy service compensation of EUR 
8.35, and the value added tax (VAT, according to the Drug 
Price Ordinance). The price for non-prescription drugs 
(pharmacy-only as well as freely available drugs) is not 
regulated and is set by the individual pharmacy or by the 
drug stores and supermarkets. The turnover of all 
community pharmacies in 2019 was EUR 54.15 billion 
(without VAT), with drug dispensing accounting for 90.7% 
(83.8% for prescribed and 6.9% [EUR 3.75 billion] for self-
medication).12 
Membership in a regional chamber of pharmacists – one in 
each of Germany’s 16 federal states (with two chambers in 
North Rhine-Westphalia) – is mandatory for every 
pharmacist. The chambers are responsible for education 
and training, professional law, and pharmaceutical quality, 
among others. Membership in one of the complementing 
17 regional associations of pharmacists, representing 
economic and commercial interests, is voluntary and 
restricted to community pharmacy owners. The Federal 
Chamber of Pharmacists [Bundesapothekerkammer; BAK] 
and the German Pharmacists' Association [Deutscher 
Apothekerverband; DAV] represent the regional institutions 
on the federal level. The ABDA – Federal Union of German 
Associations of Pharmacists is the umbrella organization of 
the 17 chambers and 17 associations.  
 
PRIMARY HEALTHCARE POLICY 
The main goal in German healthcare policy is that 
comprehensive healthcare is available for everybody 
regardless of where people live, an individual financial 
situation, age, or gender.13 The separation of outpatient 
and inpatient sectors and the lack of cooperation between 
the different healthcare providers is considered a 
fundamental problem in German healthcare.14 In recent 
years, various provisions for integrated care were 
introduced, aiming to improve cooperation and 
information flow within and between ambulatory care 
providers, community pharmacies among others, and 
hospitals.  
The action plan to improve medication safety in Germany, 
funded by the Federal Ministry of Health since 2008, and an 
innovation fund, set up in 2015 with an annual budget of 
about EUR 300 million, both promote innovations in the 
German healthcare system. The sponsoring of research 
projects, information campaigns, drug databases, and 
intervention strategies, intends to support patients, 
physicians, and pharmacists to ensure an optimal 
medication process and to improve quality of care, 
eventually.15,16 
Digital health strategy 
Although electronic documentation is common across all 
sectors, patient records are not yet exchanged 
electronically but send by letter or fax. Currently, 
prescriptions are still paper-based and there is no central 
electronic database with patients’ data on prescribed drugs 
or medical records.  
Thus, at the beginning of the millennium, the Federal 
Ministry of Health and major stakeholders in healthcare 
launched the eHealth Initiative. In 2005, the gematik was 
established by leading organizations with the aim to build a 
secure, cross-sector telematics infrastructure (TI).17 In 
2019, the Federal Ministry of Health jointed the gematik as 
a major shareholder to accelerate the development. In fact, 
progress was hampered significantly, since firstly the 
gematik only developed the standards from a technical 
point of view without being given any legal responsibility in 
Eickhoff C, Griese-Mammen N, Mueller U, Said A, Schulz M. Primary healthcare policy and vision for community pharmacy and 
pharmacists in Germany. Pharmacy Practice 2021 Jan-Mar;19(1):2248.  
https://doi.org/10.18549/PharmPract.2021.1.2248 
www.pharmacypractice.org (eISSN: 1886-3655 ISSN: 1885-642X) 3 
coordinating the technical or political development, and 
secondly consensus-based decisions often failed due to the 
different positions of the stakeholders.  
Additionally, the current Federal Ministry of Health 
established a department for digitalization and in 2016, the 
eHealth Act came into force.18,19 The TI, as the key 
component for digital healthcare, is rolled out to connect 
all healthcare providers in primary and secondary care in a 
secure network.17 Primary care physicians are currently 
connected and community pharmacies will follow by July 
2021.  
An important application within this infrastructure will be a 
safe communication between healthcare professionals 
ensuring maximum data protection. The eHealth Act 
furthermore regulates that all patients will get an electronic 
health record (EHR), starting from January 2021. 
Progressively, the EHR will include further medical 
information, an electronic medication plan, important 
information for emergencies, and vaccinations. Healthcare 
professionals will be able to access these EHR in a two-key 
authorization process by using an electronic healthcare 
professional ID card and a corresponding electronic patient 
card. Electronic prescriptions are currently being piloted 
with the aim to complete the switch from paper-based to 
electronic prescribing by January 2022.  
In December 2019, the Act for Digital Supply became 
effective regulating the prescription of SHI-remunerated 
medical apps and the implementation of video 
consultations.20 
The pharmacists’ white paper 
In 2014, the ABDA released the position paper “Pharmacy 
2030 – Perspectives on provision of pharmacy services in 
Germany”.21 Pharmacists are positioned to maintain a key 
role in primary care and to improve and increase 
collaboration with other healthcare professionals and to 
actively shape the healthcare network with clearly defined 
competencies, assuming responsibility for the safety and 
optimization of medication therapy and practices.  
Although no specific services were prioritized, the 
relevance of community pharmacy services were outlined 
in general, alongside future prospects regarding the 
pharmacists’ role in primary care.  
 
COMMUNITY PHARMACY SERVICES 
Overview  
Although many patient-oriented pharmaceutical services 
have been developed in Germany, their implementation 
appears to be slow compared to other countries.22 One 
major barrier is the lack of remuneration, with no 
reimbursed cognitive pharmaceutical services implemented 
nationwide. Many of the services developed are 
summarized in a catalogue named LeiKa, including:  
- Services linked to the medication e.g., checking 
inhalation technique, medication management, 
medication review, monitoring opioid substitution. 
- Measurement of clinical parameters e.g., blood 
pressure, blood glucose, peak flow. 
- Health promotion e.g., vaccination advice, nutrition 
counselling, smoking cessation, self-measurement of 
blood glucose, risk assessment for diabetes with 
FINDRISC. 
- Other services e.g., leasing medical devices, home 
care.23  
The BAK developed the catalogue and defined quality 
standards, which includes guidelines and requirements in 
terms of e.g., staff qualification and equipment. 
Furthermore, there are working materials available to 
facilitate implementation such as standard operating 
procedures, checklists, and documentation forms as well as 
templates for patient information and marketing 
instruments. The catalogue further suggests which 
parameters are to take into account for cost calculation. An 
example of a price covering the actual costs was agreed 
upon in the medication management project ARMIN 
described below. There, the interdisciplinary medication 
review is currently remunerated with EUR 112.10 
(excluding VAT) and the follow up interventions with EUR 
24.90 for both the pharmacist and the physician.  
Cognitive pharmaceutical services in community 
pharmacies are still not common despite the strong wish, 
especially from young pharmacists and those wishing to 
enhance job satisfaction and reputation of the profession. 
However, there is no data on the number of 
pharmaceutical services currently provided.  
Defining roles and responsibility of pharmacists and 
physicians in primary healthcare 
Cooperation between community pharmacists and 
physicians, with clarity of respective roles and 
responsibilities, is essential for effective patient care.24 
Therefore, the ABDA aims to develop a common 
understanding at the national level with different 
professional bodies and societies. A result of the ongoing 
process is the acknowledgement of pharmacist care and 
interdisciplinary care for patients with different chronic 
diseases by incorporating pharmacists’ tasks into the 
national guidelines. There is also an objective to define 
threshold values for monitoring parameters when 
pharmacists should refer the patient to a physician. For 
blood glucose and blood pressure control guideline 
worksheets have been agreed between the ABDA and the 
German Diabetes and Cardiac Societies, respectively.25,26  
Involving pharmacists in clinical practice guidelines 
Traditionally, National Disease Management/Clinical 
Practice Guidelines (NVL) were developed by committees 
composed of physicians representing the clinical 
disciplines/societies/associations. These committees are 
managed and controlled by National Physicians’ 
organisations. However, pharmacist care contributing to 
significantly improving patient outcomes as demonstrated 
in many national and international studies, led to include 
pharmacists in a number of committees developing NVLs 
and S3-guidelines:27-33  
 National Disease Management-/Clinical Practice 
Guidelines [NVL] 
o Asthma (4th ed. 2020) 
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o Chronic Heart Failure (3rd ed. 2019) 
o COPD (2nd ed. 2020) 
o Diabetes (1st comprehensive ed. 2020) 
o Hypertension (under development) 
o Unipolar Depression (under development) 
 S3 guidelines:  
o Drug-related disorders (2020) 
o Multi-medication/polypharmacy (under 
development) 
The first NVL to include pharmacists was on asthma in 
2008, based on the results of two pharmaceutical care 
studies and a study on improving patients’ inhalation 
technique.28,29,34,35 In 2013, community pharmacists were 
additionally included in the NVL diabetes.37 An 
interdisciplinary working group was established with the 
German Diabetes Society (DDG) in 2000 to discuss the role 
of community pharmacists in diabetes care.25 A curriculum 
to qualify as a “pharmacist in diabetology (BAK/DDG)” was 
developed and responsibilities and limitations of 
pharmacist’ interventions were defined.38 Furthermore, a 
study was conducted that showed the effect of individual 
patient counselling on self-measurement of blood 
glucose.30 By 2020 , approximately 1,700 pharmacists have 
participated in a certified curriculum and qualified to offer 
services for asthma and 3,700 pharmacists qualified for 
diabetes.39 
The NVL chronic heart failure describes the tasks of 
pharmacists as illustrated in Figure 1, demonstrating the 
complexity of the different tasks and interventions. 
Pharmacists’ role in blood pressure screening  
Community pharmacies can identify a significant number of 
patients with undetected/undiagnosed hypertension or 
poorly controlled blood pressure. However, national and 
European guidelines do not provide specific guidance when 
and how to refer patients with elevated blood pressure to a 
physician. In order to enable community pharmacists to 
provide recommendations based on the measured blood 
pressure values, the German Society of Cardiology (DGK) 
and the ABDA developed and tested referral 
recommendations for community pharmacists. These 
recommendations are embedded in two different 
worksheets, published nationally and internationally that 
are available online (https://doi.org/10.1111/jch.14020). They 
guide community pharmacists screening patients with 
suspected or known hypertension.26  
Three risk categories were defined including 
recommendations for action and urgency depending on the 
measured values. It was shown, that these guideline-
directed blood pressure measurements, documentation, 
and application of referral criteria are feasible in German 
community pharmacies. In addition, evaluation of the 
worksheets in a study with 187 individuals (86 with known 
hypertension, 101 without known hypertension from 17 
community pharmacies) uncovered 16% of patients with 
undetected/undiagnosed hypertension and 55% of 
hypertensive patients with poorly controlled blood 
pressure, illustrating the potential public health 
importance.26 Data on the extent of implementation in 
daily community pharmacy practice are currently not 
available. 
Pharmacists’ role in diabetes prevention 
The role of pharmacists in the prevention of diabetes was 
defined by the above mentioned interprofessional working 
group.25 It was agreed, that pharmacists are highly qualified 
and have frequent contacts (approx. 1.6 million per day) to 
the general population.12 Thus the development of 
programs to establish pharmacists as “prevention 
managers” was recommended.41 An example for such a 
Prevention:
- Improving adherence to antihypertensive
medication, among others
(including blood pressure measurement
and control)
Early detection:
- Check request for self-medication
(use of OTC medication) for symptoms or
signs of heart failure refer to physician
Medication review and medication safety:
- Consider co-morbidities and prescriptions
by other specialists
- Check for inappropriate medication
including OTC, drug/drug interactions, 
double medication and medication errors
Pharmaceutical care:
- Above all, monitor and improve adherence/
persistence to evidence-based medication
- Consider dose dispensing / providing
medication in weekly dosing aids (eg
dosette)
Pharmacists
Figure 1. Tasks for pharmacists according to the National Disease Management/Clinical Practice Guideline Chronic 
Heart Failure, 3rd ed. 2019.
26,40,32
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program is GLICEMIA for the primary prevention of type 2 
diabetes, where pharmacists assessed the risk score with 
the FINDRISC.27,42 The intervention consisted of eight 
counselling sessions (individual or group-based) in the 
pharmacy and resulted in a significant reduction of the risk 
score. Data on the extent of implementation in daily 
community pharmacy practice are currently not available. 
The medication plan 
The German Federal Ministry of Health initiated the 
development of a standardized medication plan format as 
part of the above mentioned action plan to improve 
medication safety.43 A complete medication list was 
identified as a relevant patient safety indicator.44-46 This 
medication plan (medication schedule) is a printable 
document for the patient, listing all relevant information on 
the medication including the active ingredient (INN name), 
brand name, dosage, and indication as well as general 
information for use, if needed (Figure 2).43,47 
The practicability and acceptance of the medication plan, 
with an interprofessional cooperation of physicians and 
pharmacists in an ambulatory setting, was tested in three 
studies. One of these, the project ARMIN, is described in 
more detail below.48 Overall, the medication plan was well 
received and it seemed to contribute to patients’ 
satisfaction and facilitate interprofessional collaboration. 
The main challenges from the healthcare providers’ 
perspective were: the time needed to generate and update 
the medication plan; the missing TI; and that processes and 
responsibilities between the healthcare professionals 
needed to be defined and implemented into routine care.  
Missing processes in two of the projects resulted in 
incomplete and outdated medication plans in the majority 
of patients. Although these issues have not been solved 
yet, the medication plan was introduced nationwide in 
October 2016.19 Since then, all patients with at least three 
prescribed drugs are eligible to receive a paper-based 
medication plan. This plan is issued through a patient‘s 
request by the prescribing physician, who receives a small 
honorarium. Changes to the plan can be made by any other 
physician as well as the pharmacist without being 
remunerated. The lack of remuneration has been criticized 
by the pharmacists organizations.49 In addition, processes 
and responsibilities are not yet defined that would ensure 
that this medication plan is complete (with regard to both, 
prescribed and OTC drugs), checked for patient safety 
including drug-related problems, and regularly updated. As 
a result, the medication plan is not yet widespread in 
Germany.  
However, it is expected that the implementation of the TI 
will promote the electronic medication plan (eMP). This will 
be an electronic version of the paper-based plan with 
additional information for healthcare providers on e.g., 
pregnancy, breastfeeding, kidney function, and allergies of 
the patients.  
 
CURRENT PROJECTS ON PHARMACEUTICAL 
SERVICES  
Influenza vaccination 
Influenza vaccination in community pharmacies has already 
been successfully introduced in many countries. In 
Germany, there has been some reluctance to follow that 
example mainly due to protests from the medical 
profession, although the vaccination coverage in the 
population at risk is low.50  
To increase the number of influenza vaccinations, 
pharmacists are legally allowed to administer this 
vaccination from March 2020 within “model projects”.51 
Pharmacists delivering this service have to qualify by 
participating in an advanced training. The curriculum was 
developed by the BAK in cooperation with the Robert Koch-
Institute (RKI), which is the government’s central scientific 
institution in the field of biomedicine and one of the most 
Figure 2. Medication plan format (unauthorized English translation) 
born: 13.12.1936
Seite 1 von 1 issued by:
Dr. Helga Herz
Hauptstraße 55, 01234 Am Ort
Tel.: 04562-12345
E-Mail: h.herz@mein-netz.de issue date: 16.10.2020
Active ingredient Strength Form Unit Instructions Indication
Magnesiumoxid 250mg Caps 0 0 1  Pcs Cramps
Metoprololsuccinat 95mg Tabl ½ 0 0 Pcs Heart failure
Omeprazol 20mg Tabl 1 0 1 Pcs Heart burn
Methotrexat 15mg Tabl Pcs at night with a glass of water Joint inflammation
Metamizol natrium-1-
Wasser
500mg/ml Drops 30 30 0 30 Drops Pain
Combination Tabl 1 1 1 1 Pcs Restlessness




medication plan for: Michaela Mustermann










please meassure your blood preassure daily!
important information
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important bodies for the safeguarding of public health in 
Germany, and the Paul Ehrlich Institute (PEI), which is the 
Federal Institute (regulatory body) for Vaccines and 
Biomedicines. A guideline and working materials were 
developed to facilitate implementation.52 First contracts 
with health insurance funds were closed in October 2020 
with more to follow in 2021. These regional projects are 
limited to five years with a subsequent evaluation to decide 
whether this service will be introduced into routine care.  
Establishing medication reviews  
In Germany, there has been significant efforts to introduce 
cognitive pharmaceutical services into standard care and 
practice. Training programs, guidelines, and working 
materials have been developed, and changes in the 
legislation were achieved. Relevant milestones were:  
• Introduction of clinical pharmacy in the academic 
curriculum for pharmacists in 2001  
• Legal anchoring of medication management as a 
pharmaceutical service in 2012 in the pharmacy 
operating regulations 
• Development of advanced training concepts for 
medication review e.g., 
 Apo-AMTS and ATHINA (since 2012)  
 Curriculum of the BAK (2015) 
• Development of a guideline for medication reviews 
(2014, revision in 2017)  
Furthermore, a comprehensive concept of an 
interdisciplinary medication management approach was 
developed at the national level by the ABDA and the 
Federal Association of Statutory Health Insurance 
Physicians (KBV) in 2011.53 This ABDA/KBV-concept was 
well received politically and as a consequence, legislation 
has been changed, enabling the ARMIN project.48 
Concurrently, numerous projects have been conducted to 
develop and evaluate suitable cognitive pharmaceutical 
services. The PHARM-CHF randomized controlled trial being 
one example (described below). 
Projects to qualify pharmacists: ATHINA and Apo-AMTS  
Medication reviews are still not implemented in daily 
routine and are not a mandatory part of the university 
training of pharmacy students. Thus, two educational 
concepts Apo-AMTS and ATHINA were developed in 
parallel with the cooperation of different chambers of 
pharmacists and pharmacy schools.31,54 Pharmacists (also 
pharmacist students in Apo-AMTS) are trained on 
medication review and pharmacologically relevant topics 
linked to aspects of pharmacotherapy and medication 
safety. Additionally, the pharmacists have to conduct a 
certain number of medication reviews. Supervision by a 
medication coordinator (in Apo-AMTS) or a tutor (in 
ATHINA) allows qualified feedback on the reviews. ATHINA 
is now offered by 11 out of 17 regional chambers of 
pharmacists. However, remuneration of medication 
reviews by insurers remains an issue. Some regional 
contracts with SHI funds exist, but are always limited in 
time and patients often have to pay by themselves. Both 
programs have been evaluated showing feasibility as well 
as an effect in terms of drug-related problems being 
identified and solved by the pharmacist.31 As a limitation, 
physicians are not yet involved as cooperating partners.  
Implementing medication management: the model 
project ARMIN  
ARMIN [Arzneimittelinitiative Sachsen-Thüringen] was the 
first model project developed on the basis of the 
interdisciplinary medication management approach agreed 
upon by the ABDA and KBV at the national level.48,55 ARMIN 
is conducted in two federal states, Saxony and Thuringia, 
involving two state associations of pharmacists and 
physicians, and a large SHI fund (AOK PLUS).  
Figure 3: The medication management process in ARMIN.  
(I) initial intervention; (II) continuous management  
Initial compilation of all drugs
currently taken (brown bag
review)
Medical evaluation of the
medication list
Explaining new medication to
the patients, handing over
information material
Pharmaceutical evaluation of
the medication plan + update 
(over the counter + drugs
prescribed by specialists)
Adding newly prescribed 
medication
Identifying and solving drug-
related problems (structured
assessment)
Handing the medication plan 









Medical evaluation of the
medication plan + update 
(changing own prescriptions)





Finalizing the medication plan 
(adding brand names) 
Community pharmacist Physician
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One main achievement in ARMIN is that the processes and 
responsibilities are clearly defined, as described in Figure 3; 
i.e.  
- Clearly defined roles and responsibilities should 
facilitate the communication between the professions. 
- Defining the processes should ensure that the 
medication of the patients has been checked for risks 
and the generated medications plans are 
comprehensive and updated regularly. 
The initial intervention in ARMIN is a type 3 medication 
review according to the Pharmaceutical Care Network 
Europe’s (PCNE) definition starting with a patient interview 
in the pharmacy including a brown bag review.56 
Additionally, claims data from the SHI fund as well as data 
from the general practitioner are taken into consideration 
to complete the medication plan. After a structured 
pharmaceutical and medical risk assessment according to 
defined standards the medication plan is printed out for 
the patient.57,58 The follow-up intervention takes place 
during every patient visit in the pharmacy or general 
practice to ensure that newly dispensed medication, 
prescribed as well as self-medication, is checked and the 
medication plan is updated. Since the TI is still not 
implemented in Germany, a central server was established 
for this contract in order to be able to exchange the 
medication plans between pharmacies and physicians 
involved.  
The contract is now widely accepted and regarded as pilot 
for a successful interdisciplinary cooperation. 
Approximately 350 pharmacists and 350 general 
practitioners and 7,000 patients are currently participating.  
Generating evidence in research projects - PHARM-CHF 
PHARM-CHF was the first per patient randomized, 
controlled interdisciplinary trial in Germany to examine the 
effects of a medication review followed by structured care 
aiming to improve medication adherence.32 The 
intervention aimed to improve adherence to three heart 
failure medication classes and health-related quality of life 
in elderly patients with chronic heart failure. At baseline, a 
medication review (Type 2a) was conducted in the 
community pharmacy.56 Based on the subsequently 
consolidated medication plan, the patient received a 
weekly dosing aid together with a printout of the 
medication plan. Pharmaceutical care continued by weekly 
or bi-weekly visits to the pharmacy including counselling 
regarding medication, adherence, potential side effects, 
signs and symptoms of decompensation and measurement 
of blood pressure and pulse rate.  
The PHARM-CHF intervention improved mean adherence to 
heart failure medication and the proportion of adherent 
patients. The intervention led to a clinically meaningful 
improvement in patients’ quality of life.32 
 
NATIONWIDE IMPLEMENTATION OF COGNITIVE 
SERVICES – THE FUTURE 
On 29 October 2020, the On-site Pharmacy Strengthening 
Act was adopted by the German Parliament. A main aspect 
is the introduction and remuneration of additional 
pharmaceutical services. The type of services and their 
specific remuneration remain to be negotiated between 
the DAV and the National Association of SHI funds. The 
services should aim to improve medication effectiveness 
and safety and may lead to competition between 
pharmacies with regard to service quality. Several examples 
are given e.g. of suitable target groups (patients with 
polypharmacy as well as patients with a high need for 
counselling) and topics that should be addressed 
(medication adherence; prevention). Reference is also 
made to medication management services. A total of EUR 
150 million in annual net additional funding will be made 
available for this purpose.  
This nationwide remuneration of cognitive services, by law, 
is an important and critical step in Germany. The main 
challenge will be to implement and sustain these services in 
the majority of pharmacies, truly integrating them into 
primary care. Especially relevant will be to further develop 
already known facilitators like clinical training as well as 
strengthening the cooperation with physicians. Further 
challenges will also be the implementation of e-prescription 
and telepharmacy as well as using the new electronic data 
meaningfully. 
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